Recent advances in transgenic model development for Alzheimer's disease

Bibliography

• IQBAL K: Prevalence and neurobiology of Alzheimer'sdisease: some highlights. In: Alzheimer's Disease: Basic Mechanisms. Diagnosis and Therapeutic Strategies. Iqbal K, McLachlan DRC, Winblad B, Wisniewsky HM (Eds.), Wiley (1991).
   Google Scholar
• ALZHEIMER A: fiber eine eigenartige Erkrankung derHirnrinde. AIlg. Z. Psychiatr. (1907) 64:146–148.
   Google Scholar
• YANKNER BA: Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron (1996) 16:921–932.
   PubMed Web of Science ®Google Scholar
• GOEDERT M. Tau protein and the neurofibrillary pa-thology of Alzheimer's disease. Trends Neurosci. (1993) 16:460–465.
   PubMed Web of Science ®Google Scholar
• QUON D, WANG Y, CATALANO R et al.: Formation of 13-amyloid protein deposits in brains of transgenic mice. Nature (1991) 352:239–241.
   PubMed Web of Science ®Google Scholar
• HIGGINS LS, CATALANO R, QUON D, CORDELL B. Trans-genic mice expressing human 13APP751, but not mice expressing 9APP695, display Alzheimer's disease-like histopathology. Ann. NY Acad. Sci. (1993) 695:224–227.
   PubMed Web of Science ®Google Scholar
• HIGGINS LS, RODEMS JM, CATALANO R, QUON D, COR-DELL B: Early Alzheimer's disease-like histopathology increases in frequency with age in mice transgenic for 13APP751. Proc. Natl. Acad. Sci. USA (1995) 92:4402–4406.
   PubMed Web of Science ®Google Scholar
• MORAN PM, HIGGINS LS, CORDELL B, MOSER PC: Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human 13-amyloid pre-cursor protein. Proc. Natl. Acad. Sci. USA (1995) 92:5341–5345.
   PubMed Web of Science ®Google Scholar
• MUCKE L, MASLIAH E, JOHNSON WB et al: Synapto-trophic effects of human amyloid 0 protein precursors in the cortex of transgenic mice. Brain Res. (1994) 666:151–167.
   PubMed Web of Science ®Google Scholar
• D'HOOGE R, NAGELS G, WESTLAND CE, MUCKE L, DE DEYN PP: Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor pro-tein. Neuroreport (1996) 7:2807–2811.
   PubMed Web of Science ®Google Scholar
• LAMB BT, SISODIA SS, LAWLER AM et al.: Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice. Nature Genet. (1993) 5:22–30.
   PubMed Web of Science ®Google Scholar
• PEARSON BE, CHOI TK: Expression of the human9-am-yloid precursor protein gene from a yeast artificial chromosome in transgenic mice. Proc. Natl. Acad. Sci. USA (1993) 90:10578–10582.
   PubMed Web of Science ®Google Scholar
• BUXBAUM JD, CHRISTENSEN JL, RUEFLI AA, GREENGARD P, LORING JF: Expression of APP in brains of transgenic mice containing the entire human APP gene. Biochem. Biophys. Res. Commun. (1993) 197:639–645.
   PubMed Web of Science ®Google Scholar
• LAFERLA FM, TINKLE BT, BIEBERICH CJ, HAUDENSCHILD CC, JAY G: The Alzheimer's A13 peptide induces neuro-degeneration and apoptotic cell death in transgenic mice. Nature Genet. (1995) 9:21–29.
   PubMed Web of Science ®Google Scholar
• KAMMESHEIDT A, BOYCE FM, SPANNOYANNIS AF et al.:Deposition of 13/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the car-boxyterminal fragment of the Alzheimer amyloid pre-cursor in the brain. Proc. Natl. Acad. Sci. USA (1992) 89:10857–10861.
   PubMed Web of Science ®Google Scholar
• NEVE RL, BOYCE FM, MCPHIE DL, GREENAN J, OSTER-GRANITE ML: Transgenic mice expressing APP-C100 in the brain. Neurobiol ageing (1996) 17:191–203.
   PubMed Web of Science ®Google Scholar
• OSTER-GRANITE ML, MCPHIE DL, GREENAN J, NEVE RL:Age dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid pre-cursor protein. J. Neurosci. (1996) 16:6732–6741.
   PubMed Web of Science ®Google Scholar
• SATO M, KAWARABAYASHI T, SHOJI M et al.: Neurode-generation and gliosis in transgenic mice overex-pressing a carboxy-terminal fragment of Alzheimer amyloid-13 protein precursor. Dement. Geriatr. Cogn. Disord. (1997) 8:296–307.
   PubMed Web of Science ®Google Scholar
• NALBANTOGLU J, TIRADO-SANTIAGO G, LAHSAINI A et al: Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature (1997) 387:500–505.
   PubMed Web of Science ®Google Scholar
• LAFERLA FM, HALL CK, NGO L, JAY G: Extracellular deposition of beta-amyloid upon p53-dependent neu-ronal cell death in transgenic mice". Clin. Invest. (1996) 98:1626–1632.
   Google Scholar
• GOTZ J, PROBST A, SPILLANTINI MG et al: Somatoden-dritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest hu-man brain tau isoform. EMBO J. (1995) 14:1304–1313.
   PubMed Web of Science ®Google Scholar
• JAMES ND, DAVIS DR, SINDON J et al: Neurodegenera-tive changes including altered tau phosphorylation and neurofilament immunoreactivity in mice trans-genic for the serine/threonine kinase. Mos. Neurobiol Ageing (1996) 17:235–241.
   PubMed Web of Science ®Google Scholar
• BROWNLEES J, IRVING NG, BRION JP et al.: Tau phospho-rylation in transgenic mice expressing glycogen syn-thase kinase 313 transgenes. Neuroreport (1997) 8:3251–3255.
   PubMed Web of Science ®Google Scholar
• KAYYALI US, ZHANG W, YEE AG, SEIDMAN JG, POTTER H: Cytoskeletal changes in brains of mice lacking Cal-cineurin Act. j Neurochem. (1997) 68:1668–1678.
   PubMed Web of Science ®Google Scholar
• HARDY J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci (1997) 20:154–159.
   PubMed Web of Science ®Google Scholar
• PRICE DL, SISODIA SS: Mutant genes in familial Alz-heimer's disease and transgenic models. Ann. Rev. Neu-rosci. (1998) 21:479–505.
   PubMed Web of Science ®Google Scholar
• HOWLAND DS, SAVAGE MJ, HUNTRESS FA et al.: Mutant and native human 13-amyloid precursor proteins in transgenic mouse brain. Neurobiol. Ageing (1995) 16:685–699.
   PubMed Web of Science ®Google Scholar
• ANDRA K, ABRAMOWSKI D, DUKE M et al.: Expression of APP in transgenic mice: A comparison of neuron-specific promoters. Neurobiol. Ageing (1996) 17:183–190.
   PubMed Web of Science ®Google Scholar
• MALHERBE P, RICHARDS JG, MARTIN JR et al.: Lack of 9-amyloidosis in transgenic mice expressing low lev-els of familial Alzheimer's disease missense muta-tions. Neurobiol. Ageing (1996) 17:205–214.
   PubMed Web of Science ®Google Scholar
• CZECH C, DELAERE P, MACQ AF etal.: Proteolytical proc-essing of mutated human amyloid precursor protein in transgenic mice. Mol. Brain Res. (1997) 47:108–116.
   Google Scholar
• LAMB BT, CALL LM, SLUNT HH et al.: Altered metabolism of familial Alzheimer's disease-linked amyloid precur-sor protein variants in yeast artificial chromosome transgenic mice. Hum. Mol. Genet. (1997) 6:1535–1541.
   PubMed Web of Science ®Google Scholar
• REAUEME AG, HOWLAND DS, TRUSKO SP et al. En-hanced amyloidogenic processing of the 9-amyloid precursor protein in gene targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" A13 sequence. J. Biol. Chem. (1996) 271:23380–23388.
   PubMed Web of Science ®Google Scholar
• GAMES D, ADAMS D, ALESSANDRINI R et al.: Alzheimer- type neuropathology in transgenic mice overexpress-ing V717F 13-amyloid precursor protein. Nature (1995) 373:523–528.
   PubMed Web of Science ®Google Scholar
• HSIAO K, CHAPMAN P, NILSEN S et al.: Correlative mem-ory deficits, A13 elevation and amyloid plaques in trans-genic mice. Science (1996) 274:99–102.
   PubMed Web of Science ®Google Scholar
• STURCHLER-PIERRAT C, ABRAMOWSKI D, DUKE M et al.: Two amyloid precursor protein transgenic mouse models with Alzheimer's disease-like pathology. Proc. Natl. Acad. ScL USA (1997) 94:13287–13292.
   PubMed Web of Science ®Google Scholar
• ROCKENSTEIN EM, MCCONLOGUE L, TAN H et al.: Levelsand alternative splicing of amyloid 3 protein precur-sor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's Disease. J. Biol. Chem. (1995) 270:28257–28267.
   PubMed Web of Science ®Google Scholar
• ROUTTENBERG A: Measuring memory in a mouse model of Alzheimer's disease. Science (1997) 277:239–240.
   PubMed Web of Science ®Google Scholar
• DUFF K, ECKMAN C, ZEHR C et al: Increased amy-loid-1342(43) in brains of mice expressing mutant pre-senilin 1. Nature (1996) 383:710–713.
   PubMed Web of Science ®Google Scholar
• BORCHELT DR, THINAKARAN G, ECKMAN CB et al.: Fa-milial Alzheimer's disease-linked presenilin 1 variants elevate A131-42/1-40 ratio in vitro and in vivo. Neuron (1996) 17:1005–1013.
   PubMed Web of Science ®Google Scholar
• CITRON M, WESTAWAY D, XIA W et al.: Mutant prese-nilins of Alzheimer's disease increase production of 42-residue amyloid I3-protein in both transfected cells and transgenic mice. Nature Med. (1997) 3:67–72.
   PubMed Web of Science ®Google Scholar
• HSIAO KK, BORCHELT DR, OLSON K et al: Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron (1995) 15:1203–1218.
   PubMed Web of Science ®Google Scholar
• BORCHELT DR, RATOVITSKI T, VAN LARE J et al: Acceler-ated amyloid deposition I the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron (1997) 19:939–945.
   PubMed Web of Science ®Google Scholar
• HOLCOMB L, GORDON MN, MCGOWAN E et al.: Acceler-ated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med (1998) 4:97–100.
   PubMed Web of Science ®Google Scholar
• MASLIAH E, SISK A, MALLORY M et al: Comparison of neurodegenerative pathology in transgenic mice over-expressing V717F 13-amyloid precursor protein and Alzheimer's disease. J. Neurosci. (1996) 16:5795–5811.
   PubMed Web of Science ®Google Scholar
• JOHNSON-WOOD K, LEE M, MOTTER R et al.: Amyloid precursor protein processing and A042 deposition in a transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. ScL USA (1997) 94:1550–1555.
   PubMed Web of Science ®Google Scholar
• IRIZARRY MC, SORIANO F, MCNAMARA M et al: Af3 depo-sition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid pre-cursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. (1997) 17:7053–7059.
   PubMed Web of Science ®Google Scholar
• IRIZARRY MC, MCNAMARA M, FEDORCHAK K, HSIAO K,HYMAN BT: APPSw transgenic mice develop age-related Af3 deposits and neuropil abnormalities, but no neuronal loss in CAL J. Neuropath. Expd. Neurol (1997) 56:965–973.
   PubMed Web of Science ®Google Scholar
• SMITH MA, HIRAI K, HSIAO K et al: Amyloid-I3 deposi-tion in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. (1998) 70:2212–2215.
   PubMed Web of Science ®Google Scholar
• CALHOUN ME, WIEDERHOLD K-H, ABRAMOWSKI D et Amyloid plaques and neuronal death in APP trans-genic mice. Nature (1998) 395:755–756.
   PubMed Web of Science ®Google Scholar
• WEST MJ, COLEMAN PD, FLOOD DG, TRONCOSO JC: Dif-ferences in the pattern of hippocampal neuron loss in normal ageing and Alzheimer's disease. Lancet (1994) 344:769–772.
   PubMed Web of Science ®Google Scholar
• REGEUR L, BADSBERG JENSEN G, PAKKENBERG H, EVANS SM, PAKKENBERG B. No global neocortical nerve cell loss in brains from patients with senile de-mentia of Alzheimer's type. NeurobioL Ageing (1994) 15:347–352.
   PubMed Web of Science ®Google Scholar
• GOMEZ-ISLA T, PRICE J, MCKEEL D et al.: Profound lossof layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. (1996) 16:4491–4500.
   PubMed Web of Science ®Google Scholar
• CALHOUN ME, ABRAMOWSKI D, WIEDERHOLD K-H et al. Impact of amyloid plaques on neuron number, synaptic bouton number, and cholinergic fiber length in a transgenic mouse model of Alzheimer's disease. Soc. Neurosci. Abstr. (1997) 23(2):1637.
   Google Scholar
• SILVA AJ, SIMPSON EM, TAKAHASHI JS et al.: Mutant mice and neuroscience: recommendations concerning ge-netic background. Neuron (1997) 19:755–759.
   PubMed Web of Science ®Google Scholar
• JUCKER M, WALKER LC, MARTIN LJ et al.: Age-associated inclusions in normal and transgenic mouse brain. Sci-ence (1992) 255:1443–1445.
   PubMed Web of Science ®Google Scholar
• ALT SM, SIEDLAK SL, GONZALES-DEWHITT PA et al.: Arti-factual strain-specific signs of incipient brain amyloi-dosis in APP transgenic mice. Neurobiol. Ageing (1996) 17:223–234.
   PubMed Web of Science ®Google Scholar
• CARLSON GA, BORCHELT DR, DAKE A et al.: Geneticmodification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum. Mol. Genet. (1997) 6:1951–1959.
   PubMed Web of Science ®Google Scholar
• LOGUE SF, OWEN EH, RASMUSSEN DL, WEHNER JM: As-sessment of locomotor activity, acoustic and tactile startle, and prepulse inhibition of startle in inbred mouse strains and Fl hybrids: implications of genetic background for single gene and quantitative trait loci analyses. Neuroscience (1997) 80:1075–1086.
   PubMed Web of Science ®Google Scholar
• OWEN EH, LOGUE SF, RASMUSSEN DL, WEHNER JM: As-sessment of learning by the Morris water maze task and fear conditioning in inbred mouse strains and Fl hybrids: implications of genetic background for single gene mutations and quantitative trait loci analyses. Neuroscience (1997) 80:1087–1099.
   PubMed Web of Science ®Google Scholar
• GEULA C, WU C-K, SAROFF D et al.: Ageing renders the brain vulnerable to amyloid I3-protein neurotoxicity. Nature Med. (1998) 4:827–831.
   PubMed Web of Science ®Google Scholar